BCR and diffuse large B-cell lymphoma: Overall, our findings suggest that the BCR signaling pathway is more active in DEL compared with other DLBCL subgroups and raise the possibility for targeting the BCR signaling pathway with agents, such as ibrutinib, in this inferior prognostic subgroup of DLBCL.